IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OIPE								
In re Patent Application of								
VERVAET et al.			JUL 2 5 2006	Atty. Ref.:	2551-170			
Serial	No.	10/537,301	PARADEMAN OF	Group:	1651			
Filed:	Jur	ne 2, 2005		Examiner:	Singh			
For: PHARMACEUTICAL COMPOSITIONS OF CELL LYSATE AND PROCESSES FOR THE PRODUCTION AND USE THEREOF								
		* *	* * * * *	* * * *				
Commissioner for Patents July 25, 2006								
P.O. Box 1450 Alexandria, VA 22313-1450								
Sir:								
INFORMATION DISCLOSURE STATEMENT								
	1.	PTO-1449 Pursu [within 3 months of		97(b) 1st Office Action c	on the merits] <i>N/C</i>			
	2.(a)	Statement Pursu [before Final Office Statement or Rule	e Action or Allow	. 97(c) ance (requires Rul	e 97(e) N/C			
\boxtimes	2 .(b)	Fee Payment Pu [before Final Office Statement or Rule	e Action or Allow	R 1.97(c) ance (requires Rul	e 97(e) <i>\$180.00</i>			
	3.	•	Action or Allowar	nce (requires Rule before final fee pa	• •			

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

• • • • •		0				
	4.	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.				
This paper is submitted in accordance with:						
	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]				
\boxtimes	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and				
		a)	The required Statement made in item 8 below; or			
	\boxtimes	b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.			
			CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) tement and Rule 17(p) fee), but before final fee payment]; and			
		a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and			
		b)	The required Statement is stated in item 8 below.			
	8.	Statement under 37 CFR 1.97(e)				
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or			
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			

VERVAET et al. Serial No. 10/537,301

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

Reg. No. 36,663

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

- 3 -

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)